Remarks

The above amendments are being made to correct a typographical error which was inadvertently made in the preliminary amendment filed March 18, 2002. A copy of the claims marked to show the changes made is attached. The amendment brings tile claims into compliance with the priority case PCT/CA00/01132. No new matter has been added.

No fee is believed necessary to enter this amendment. However if a fee is necessary, please charge Deposit Account 17-0055.

Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to examination and consideration of the above-identified application.

QUARLES & BRADY LLP

BY:

Terri S. Flynn, Reg. No. 43,756

Date: July 25, 2002

QUARLES & BRADY 411 East Wisconsin Avenue Milwaukee WI 53202-4497 U.S.A. (414) 277-5229

MARKED UP VERSION OF THE CLAIMS

- 2. The use as defined in claim 1, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 1 to 5000 $\mu[p]g/Kg$ of patient's body weight.
- 3. The use, as defined in claim 1, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 10 to 50 μ [p]g/Kg of patient's body weight.
- 4. The use as defined in claim 1, wherein 17- β estradiol or a derivative thereof is present in a dose unit of 10 to 30 $\mu[p]g/Kg$ of patient's body weight.